About Us  |  BVA-100  |  Investor Relations  |  Idant Division  |  Contact Us
 

ABOUT US: company

 
 

8/13/2008 -Daxor Announces a Union Hospital Purchase and a Separate Trial of Blood Volume Analyzer BVA-100.

  

7/31/2008 -(AMEX: DXR) Daxor Corporation Announces Second Quarter 2008 Earnings

  

7/16/2008 -Daxor Announces International Publication of Clinical Study Involving Critically Ill Surgical Patients and Avoidance of Blood Transfusion Errors.

  
 

______________________

 
     
  2008 Proxy Statement  
  2008 Second Quarter Earnings  
  June 2008 10Q  
  2007 Annual Report  
 

Daxor is a publicly traded company registered in the American Stock Exchange (DXR). We are an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient's blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility.

Our IDANT division provides (1) semen banking services, which include anonymous donor semen and semen storage, (2) autologous blood storage, (3) andrology services, which include semen analysis and sperm washing, and (4) general lab testing.

Ultimately the company's mission is to help hospitals and physicians incorporate Daxor's advanced technologies to significantly improve the quality of patient care.


Menu Options

Home Page

Mission Statement

Privacy Statement

Company Management

Careers

Contact Us

 

 

Corporate
Headquarters

350 Fifth Ave.
Suite 7120
New York, NY 10118
Phone: 212-330-8500
Fax: 212-244-0806


2007 Daxor Corporation. All Rights Reserved.